Yale University

Publications

Filters: Author is BHIVES Collaborative  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Schackman, Bruce R., Jared A. Leff, Michael Botsko, David A. Fiellin, Fredrick L. Altice, Todd P. Korthuis, Nancy Sohler, Linda Weiss, James E. Egan, Julie Netherland et al. "The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S76-82. Abstract
D
Fiellin, David A., Linda Weiss, Michael Botsko, James E. Egan, Frederick L. Altice, Lauri B. Bazerman, Amina Chaudhry, Chinazo O. Cunningham, Marc N. Gourevitch, Paula J. Lum et al. "Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
F
Netherland, Julie, Michael Botsko, James E. Egan, Andrew J. Saxon, Chinazo O. Cunningham, Ruth Finkelstein, Mark N. Gourevitch, John A. Renner, Nancy Sohler, Lynn E. Sullivan et al. "Factors affecting willingness to provide buprenorphine treatment." Journal of substance abuse treatment 36, no. 3 (2009): 244-51. Abstract
H
Vergara-Rodriguez, Pamela, Mary Jo Tozzi, Michael Botsko, Vijay Nandi, Frederick Altice, James E. Egan, Patrick G. O'Connor, Lynn E. Sullivan, and David A. Fiellin. "Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S62-7. Abstract
Altice, Frederick L., Douglas R. Bruce, Gregory M. Lucas, Paula J. Lum, Todd P. Korthuis, Timothy P. Flanigan, Chinazo O. Cunningham, Lynn E. Sullivan, Pamela Vergara-Rodriguez, David A. Fiellin et al. "HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
I
Sullivan, Lynn E., Michael Botsko, Chinazo O. Cunningham, Patrick G. O'Connor, David Hersh, Jennifer Mitty, Paula J. Lum, Richard S. Schottenfeld, and David A. Fiellin. "The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
Korthuis, Todd P., Mary Jo Tozzi, Vijay Nandi, David A. Fiellin, Linda Weiss, James E. Egan, Michael Botsko, Angela Acosta, Marc N. Gourevitch, David Hersh et al. "Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
Korthuis, Todd P., David A. Fiellin, Rongwei Fu, Paula J. Lum, Frederick L. Altice, Nancy Sohler, Mary J. Tozzi, Steven M. Asch, Michael Botsko, Margaret Fishl et al. "Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
Weiss, Linda, Julie Netherland, James E. Egan, Timothy P. Flanigan, David A. Fiellin, Ruth Finkelstein, and Frederick L. Altice. "Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
O
Lum, Paula J., Sherri Little, Michael Botsko, David Hersh, Robert E. Thawley, James E. Egan, Jennifer Mitty, Joshua Boverman, and David A. Fiellin. "Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S91-7. Abstract
P
Chaudhry, Amina A., Michael Botsko, Linda Weiss, James E. Egan, Jennifer Mitty, Barbara Estrada, Gregory M. Lucas, Tanita Woodson, Timothy P. Flanigan, and David A. Fiellin. "Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract